Highlights zum Urothel- und Nierenzellkarzinom

Vimeo

Mit dem Laden des Videos akzeptieren Sie die Datenschutzerklärung von Vimeo.
Mehr erfahren

Video laden

  • Verwenden Sie folgende Direktlinks, um im Video zu navigieren:
  • 00:37 - ATLANTIS-Studie
  • 02:17 - COSMIC-021-Studie
  • 03:40 - EV-301-Studie
  • 04:45 - EVERES
  • 06:28 - CheckMate 9ER
  • 08:14 - CheckMate 214

 

 

ATLANTIS-Studie: Jones RJ et al., A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison.

COSMIC-021-Studie: Pal SK et al., Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study.

EV-301-Studie: Rosenberg JE et al., Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.

EVEREST: Ryan CW et al., EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).

CheckMate 9ER: Suárez C et al., Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER.

CheckMate 214: Cella D et al., The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214.